Objectives To assess the effectiveness and safety of tocilizumab, a humanised anti‐
interleukin‐6 receptor antibody, in the treatment of critical or severe coronavirus disease …

What is known and objective The coronavirus disease 2019 (COVID‐19) associated
cytokine activation can lead to a rapid progression into respiratory failure, shock and …

Background The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill
hospitalized patients with coronavirus disease 2019 (COVID-19) is uncertain. Methods To …

Background SARS-CoV-2 is associated with a severe inflammatory response contributing to
respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Background The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms
to severe complications, including acute respiratory distress syndrome. In this syndrome …

Introduction: Tocilizumab, can be used in the treatment of COVID-19 in patients developing
cytokine storms. This study retrospectively evaluated patients treated with Tocilizumab …

Background Severe and critical COVID-19 disease is characterized by hyperinflammation
involving pro-inflammatory cytokines, particularly IL-6. Tocilizumab is a monoclonal antibody …